keyword
MENU ▼
Read by QxMD icon Read
search

abscopal effect

keyword
https://www.readbyqxmd.com/read/28291902/review-of-the-mechanisms-involved-in-the-abscopal-effect-and-future-directions-with-a-focus-on-thymic-carcinoma
#1
Paul Lesueur, François Chevalier, Dinu Stefan, Jean-Louis Habrand, Delphine Lerouge, Radj Gervais
The abscopal effect is a rare phenomenon in radiotherapy, leading to impressive tumor regression outside the radiotherapy field. In this article we describe the occurrence of a postradiotherapy abscopal effect in an 89-year-old patient suffering from a metastatic neuroendocrine large-cell thymic carcinoma, the first case of the abscopal effect related to a thymic carcinoma reported in the literature. Along with the description of this case, we discuss and review the main potential mechanisms of bystander and abscopal effects in solid tumors so as to enable clinicians to identify and control these effects more resourcefully in the age of immunotherapy and stereotactic radiotherapy...
March 3, 2017: Tumori
https://www.readbyqxmd.com/read/28275377/impact-of-particle-irradiation-on-the-immune-system-from-the-clinic-to-mars
#2
REVIEW
Rodrigo Fernandez-Gonzalo, Sarah Baatout, Marjan Moreels
Despite the generalized use of photon-based radiation (i.e., gamma rays and X-rays) to treat different cancer types, particle radiotherapy (i.e., protons and carbon ions) is becoming a popular, and more effective tool to treat specific tumors due to the improved physical properties and biological effectiveness. Current scientific evidence indicates that conventional radiation therapy affects the tumor immunological profile in a particular manner, which in turn, might induce beneficial effects both at local and systemic (i...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28267380/abscopal-effect-of-metastatic-pancreatic-cancer-after-local-radiotherapy-and-granulocyte-macrophage-colony-stimulating-factor-therapy
#3
Fang Shi, Xin Wang, Feifei Teng, Li Kong, Jinming Yu
The role of immunotherapy in combination with traditional treatment regime in improving the survival of cancer patients has attracted more and more attention. Especially the abscopal effect that describes the phenomenon of localized radiotherapy leading to regression of distant unirradiated tumors and the role of enhanced radiotherapy-induced immunogenic cell death and activation of immune system have become a focus of the studies. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is known a powerful stimulator of the generation, migration and activation of antigen presenting cells such as dendritic cells (DC) and macrophages...
March 7, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28236557/photons-radiobiological-issues-related-to-the-risk-of-second-malignancies
#4
Loredana G Marcu
Photons are widely used in radiotherapy and while they are low LET radiation, can still pose a risk in developing second malignant neoplasms (SMN). Due to the physics of photons that allow distribution of energy outside the target volume, out-of-field irradiation is an important component of SMN risk assessment. The epidemiological evidence supporting this risk should be augmented with radiobiological justifications for a better understanding of the underlying processes. There are several factors that impact second cancer risk which can be analysed from a radiobiological perspective: age at irradiation, type of irradiated tissue, irradiated volume, treatment technique, previous irradiation/radiological investigations...
February 21, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28230241/results-of-a-phase-ii-open-label-non-comparative-study-of-intralesional-pv-10-followed-by-radiotherapy-for-the-treatment-of-in-transit-or-metastatic-melanoma
#5
Matthew Foote, Tavis Read, Janine Thomas, Michael Wagels, Bryan Burmeister, B Mark Smithers
BACKGROUND: In-transit and recurrent dermal or subcutaneous melanoma metastases represent a significant burden of advanced disease. Intralesional Rose Bengal can elicit tumor selective ablation and a T-cell mediated abscopal effect in untreated lesions. A subset of patients in a phase II trial setting received external beam radiotherapy to their recurrent lesions with complete or partial response and no significant acute radiation reaction. METHODS: An open-label, single-arm phase II study was performed to assess the efficacy and safety of PV-10 followed by hypofractionated radiotherapy...
February 23, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28222111/a-meta-analysis-of-the-abscopal-effect-in-preclinical-models-is-the-biologically-effective-dose-a-relevant-physical-trigger
#6
Raffaella Marconi, Silvia Strolin, Gianluca Bossi, Lidia Strigari
BACKGROUND: Preclinical in vivo studies using small animals are considered crucial in translational cancer research and clinical implementation of novel treatments. This is of paramount relevance in radiobiology, especially for any technological developments permitted to deliver high doses in single or oligo-fractionated regimens, such as stereotactic ablative radiotherapy (SABR). In this context, clinical success in cancer treatment needs to be guaranteed, sparing normal tissue and preventing the potential spread of disease or local recurrence...
2017: PloS One
https://www.readbyqxmd.com/read/28214087/targeting-the-pd-1-pd-l1-axis-in-non-small-cell-lung-cancer
#7
REVIEW
Rajiv Kumar, Dearbhaile Collins, Saoirse Dolly, Fiona McDonald, Mary E R O'Brien, Timothy A Yap
The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). The proven antitumor efficacy coupled with low rates of drug-related toxicities observed, albeit idiosyncratic, with these novel immunotherapeutics have led to the registration of multiple PD-1 and PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, in second-line advanced NSCLC, whereas durvalumab and avelumab are in late-phase clinical testing...
December 23, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/28116088/radiotherapy-and-mva-muc1-il-2-vaccine-act-synergistically-for-inducing-specific-immunity-to-muc-1-tumor-antigen
#8
Gilda G Hillman, Lyndsey A Reich, Shoshana E Rothstein, Lisa M Abernathy, Matthew D Fountain, Kali Hankerd, Christopher K Yunker, Joseph T Rakowski, Eric Quemeneur, Philippe Slos
BACKGROUND: We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune response to MUC1 tumor antigen, we have tested the efficacy of tumor irradiation combined with an MVA-MUC1-IL2 cancer vaccine (Transgene TG4010) for murine renal adenocarcinoma (Renca) cells transfected with MUC1. METHODS: Established subcutaneous Renca-MUC1 tumors were treated with 8 Gy radiation on day 11 and peritumoral injections of MVA-MUC1-IL2 vector on day 12 and 17, or using a reverse sequence of vaccine followed by radiation...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28109401/melanoma-last-call-for-radiotherapy
#9
REVIEW
Sophie Espenel, Alexis Vallard, Chloé Rancoule, Max-Adrien Garcia, Jean-Baptiste Guy, Cyrus Chargari, Eric Deutsch, Nicolas Magné
Melanoma is traditionally considered to be a radioresistant tumor. However, radiotherapy and immunotherapy latest developments might upset this radiobiological dogma. Stereotactic radiotherapy allows high dose per fraction delivery, with high dose rate. More DNA lethal damages, less sublethal damages reparation, endothelial cell apoptosis, and finally clonogenic cell dysfunction are produced, resulting in improved local control. Radiotherapy can also enhance immune responses, inducing neoantigens formation, tumor antigen presentation, and cytokines release...
February 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28094262/radiotherapy-and-immunotherapy-a-beneficial-liaison
#10
REVIEW
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu
Investigations into the interaction between radiotherapy and the host immune system have uncovered new mechanisms that can potentially be exploited to improve the efficacy of radiotherapy. Radiation promotes the release of danger signals and chemokines that recruit inflammatory cells into the tumour microenvironment, including antigen-presenting cells that activate cytotoxic T-cell function. By contrast, radiation can attract immunosuppressive cells into the tumour microenvironment. In rare circumstances, the antitumour effect of radiotherapy has been observed outside of the radiation field, known as the abscopal effect...
January 17, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28072716/pneumonitis-in-cancer-patients-receiving-anti-pd-1-and-radiotherapies-three-case-reports
#11
Chieh-Sheng Lu, Jin-Hwang Liu
INTRODUCTION: In development of novel therapies for the treatment of patient with cancer, the use of radiotherapy (RT) can produce significant local control and, in recent studies, has also been shown to mediate anti-tumor responses at distant sites by triggering and enhancing the endogenous cellular immune responses. Although RT induces an abscopal effect in some patients due to enhanced immune response to the tumor, immune-escape mechanisms, including up-regulation of programmed death-ligand 1 (PD-L1) on tumor cells, limit this benefit in other patients...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27976881/photodynamic-therapy-mediated-by-nontoxic-core-shell-nanoparticles-synergizes-with-immune-checkpoint-blockade-to-elicit-antitumor-immunity-and-antimetastatic-effect-on-breast-cancer
#12
Xiaopin Duan, Christina Chan, Nining Guo, Wenbo Han, Ralph R Weichselbaum, Wenbin Lin
An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the battle against cancer, especially the metastatic disease. Checkpoint blockade-based immunotherapies have been shown to be extraordinarily effective but benefit only the minority of patients whose tumors have been pre-infiltrated by T cells. Here, we show that Zn-pyrophosphate (ZnP) nanoparticles loaded with the photosensitizer pyrolipid (ZnP@pyro) can kill tumor cells upon irradiation with light directly by inducing apoptosis and/or necrosis and indirectly by disrupting tumor vasculature and increasing tumor immunogenicity...
December 28, 2016: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/27931845/immuno-oncology-allying-forces-of-radio-and-immuno-therapy-to-enhance-cancer-cell-killing
#13
REVIEW
Jacques Bernier
Besides the local effects of ionizing radiation at the cellular and molecular levels in tumor tissues, the interactions of radiotherapy with the host's immune system are nowadays at the center of many investigations. In some cases, these interactions can be strong enough to immunize the patient against the tumor, leading to a rejection by the host of both the irradiated tumor and distant metastases. In this latter case, the rejection mechanism is called "abscopal effect". Over the last two decades, increasing attention has also been paid to the combination of various forms of immunotherapies with radiation, as an attempt to boost cancer cell killing mechanisms...
December 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27922336/abscopal-regression-following-sabr-for-non-small-cell-lung-cancer-a-case-report
#14
Yang Cong, Ge Shen, Shikai Wu, Ruimin Hao
Out-of-field tumor response, which is also called abscopal effect, bystander effect, or non-target effect, can be regarded as localized irradiation induced systemic antitumorigenic effects, indicating shrinkage of a tumor distant from the irradiated site. Although abscopal effect has been documented in several tumor types, it is a very rare phenomenon which is clinically reported in non-small-cell-lung carcinoma (NSCLC). Herein, we present a rare case of patient with NSCLC with 2 lesions in the upper lobe of left lung who, after receiving stereotactic ablative radiation therapy (SABR) to one of the tumors, had an apparent spontaneous regression of the other mass in the lung, suggestive of a radiation-induced abscopal effect...
January 2, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27910826/enhancing-radiotherapy-for-lung-cancer-using-immunoadjuvants-delivered-in-situ-from-new-design-radiotherapy-biomaterials-a-preclinical-study
#15
Yao Hao, Sayeda Yasmin-Karim, Michele Moreau, Neeharika Sinha, Erno Sajo, Wilfred Ngwa
Studies show that radiotherapy of a primary tumor in combination with immunoadjuvants (IA) can result in increased survival or immune-mediated regression of metastasis outside the radiation field, a phenomenon known as abscopal effect. However, toxicities due to repeated systematic administration of IA have been shown to be a major obstacle in clinical trials. To minimize the toxicities and prime a more potent immune response, Ngwa et al have proposed that inert radiotherapy biomaterials such as fiducials could be upgraded to multifunctional ones loaded with IA for in situ delivery directly into the tumor sub-volume at no additional inconvenience to patients...
December 21, 2016: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27905824/improved-survival-and-complete-response-rates-in-patients-with-advanced-melanoma-treated-with-concurrent-ipilimumab-and-radiotherapy-versus-ipilimumab-alone
#16
Kristian M Koller, Heath B Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D Schell, Colette Pameijer, Rogerio I Neves, Bryan Anderson, Kathleen M Kokolus, Carol A Mallon, Joseph J Drabick
There is a growing body of evidence supporting the synergistic roles of radiotherapy and immunotherapy in the treatment of malignancy. Published case studies of the abscopal effect have been reported with the use of ipilimumab and radiotherapy in metastatic melanoma, but evidence supporting the routine use of this combination of therapy is limited. We conducted a retrospective analysis to evaluate patients treated with ipilimumab for advanced melanoma at a single institution from May 2011 to June 2015. Patients were grouped into those who had received concurrent radiotherapy while on ipilimumab (Ipi-RT), and those who did not...
January 2, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27898612/rationale-for-harnessing-the-abscopal-effect-as-potential-treatment-for-metastatic-uveal-melanoma
#17
Sean A Batson, Mark P Breazzano, Ronald W Milam, Eric Shinohara, Douglas B Johnson, Anthony B Daniels
No abstract text is available yet for this article.
2017: International Ophthalmology Clinics
https://www.readbyqxmd.com/read/27821498/established-t-cell-inflamed-tumors-rejected-after-adaptive-resistance-was-reversed-by-combination-sting-activation-and-pd-1-pathway-blockade
#18
Ellen Moore, Paul E Clavijo, Ruth Davis, Harrison Cash, Carter Van Waes, Young Kim, Clint Allen
Patients with head and neck squamous cell carcinoma harbor T cell-inflamed and non-T cell-inflamed tumors. Despite this, only 20% of patients respond to checkpoint inhibitor immunotherapy. Lack of induction of innate immunity through pattern-recognition receptors, such as the stimulator of interferon (IFN) genes (STING) receptor, may represent a significant barrier to the development of effective antitumor immunity. Here, we demonstrate robust control of a T cell-inflamed (MOC1), but not non-T cell-inflamed (MOC2), model of head and neck cancer by activation of the STING pathway with the synthetic cyclic dinucleotide RP,RP dithio-c-di-GMP...
December 2016: Cancer Immunology Research
https://www.readbyqxmd.com/read/27820978/abscopal-effect-of-radiotherapy-in-a-patient-with-metastatic-diffuse-type-giant-cell-tumor
#19
Ingrid M E Desar, Pètra M Braam, Suzanne E J Kaal, Winald R Gerritsen, Wim J G Oyen, Winette T A van der Graaf
No abstract text is available yet for this article.
December 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27764686/concurrent-irradiation-with-the-anti-programmed-cell-death-ligand-1-immune-checkpoint-blocker-durvalumab-single-centre-subset-analysis-from-a-phase-1-2-trial
#20
Antonin Levy, Christophe Massard, Jean-Charles Soria, Eric Deutsch
PURPOSE: To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in combination with radiotherapy (RT) in an expansion cohort of patients included in a phase 1/2 trial at our institution. PATIENTS AND METHODS: Data from patients who received concurrent palliative RT with durvalumab (10 mg/kg every 2 weeks via intravenous infusion) were analysed in terms of safety (CTCAE v4.0) and efficacy (RECIST v1.1 and tumour growth rate [TGR])...
November 2016: European Journal of Cancer
keyword
keyword
15025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"